Form 4: Mineralys Therapeutics Director Transfers Stock Options to Catalys Pacific Fund

Brian Taylor Slingsby, a director at Mineralys Therapeutics, transferred 22,000 stock options to Catalys Pacific Fund, LP.

Summary

• Brian Taylor Slingsby, a director and 10% owner of Mineralys Therapeutics, transferred 22,000 stock options to Catalys Pacific Fund, LP on May 22, 2024.
• The stock options have an exercise price of $12.52 and expire on May 22, 2034.
• The options vest in 12 equal monthly installments starting June 22, 2024, with full vesting upon the next annual meeting if it occurs before May 22, 2025.
• Catalys Pacific Fund, LP, is deemed to have indirect beneficial ownership of these options.
• Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, which is the general partner of Catalys Pacific Fund GP, LP, the general partner of Catalys Pacific Fund, LP.

Sentiment

Score: 5

Explanation: The document is a routine filing related to stock option transfers, with no significant positive or negative implications.

Industry Context

This is a standard SEC Form 4 filing, which is common for reporting changes in beneficial ownership by company insiders. It reflects a transfer of stock options between a director and a related investment fund.

Comparison to Industry Standards

• The transfer of stock options to a related fund is a common practice among company directors and executives.
• The vesting schedule of 12 monthly installments is a typical vesting structure for stock options.
• The use of an option transfer agreement is a standard method for transferring stock options.

Related Party Transactions

• The transfer of stock options from Brian Taylor Slingsby to Catalys Pacific Fund, LP is a related party transaction.

Stakeholder Impact

• The transfer of stock options does not have a direct impact on shareholders, employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, beneficial ownership, director, transfer, Mineralys Therapeutics, Catalys Pacific Fund, vesting